Composition, form of production and packaging
? Powder for the preparation of solution for oral administration is easily flowable, granular.
With the taste of lemon: granules from white to light yellow with a slight smell of lemon; The reconstituted solution is clear or almost transparent of light yellow color.
With the taste of an orange: granules from white to light orange with a slight smell of orange; the reconstituted solution is transparent or almost transparent of light orange color.
With the taste of raspberries: granules from white to light pink with a slight smell of raspberries; the reconstituted solution is transparent or almost transparent of light crimson color.
1 pack.
paracetamol 325 mg
Pheniramine maleate 20 mg
phenylephrine hydrochloride 10 mg
ascorbic acid 50 mg
Excipients: povidone 25 mg, mannitol 2 g, calcium phosphate 30 mg, sucrose 11.29 g, citric acid 1 g, sodium citrate 100 mg, aspartame 10 mg, flavor orange, raspberry or lemon 140 mg.
15 g - Sachets of composite material (5) - packs of cardboard.
15 g - Sachets of combined material (10) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Combined drug.
Paracetamol - a non-narcotic analgesic, affecting the centers of pain and thermoregulation, has an analgesic and antipyretic effect.
Phenyramin - blocker of H 1 -gistamine receptors, reduces rhinorrhea and lacrimation, eliminates spastic phenomena.
Phenylephrine is an adrenomimetic with a moderate vasoconstrictor effect (stimulation of alpha 1- adrenoreceptors).
Ascorbic acid participates in the regulation of oxidation-reduction processes, carbohydrate metabolism, blood coagulability, tissue regeneration, in the synthesis of steroid hormones; increases the body's resistance to infections, reduces vascular permeability; reduces the need for vitamins B 1 , B 2 , A, E, folic acid, pantothenic acid. It improves paracetamol tolerance and lengthens its action (due to the elongation of T 1/2 ).
INDICATIONS
- symptomatic treatment of "colds", ARVI, incl. influenza (febrile syndrome, pain syndrome, rhinorrhea).
DOSING MODE
Inside.
Dissolve the contents of one sachet in 1 glass of boiled hot water. To use in a hot kind. You can add sugar to taste. Repeated dose can be taken every 4 hours (no more than 4 doses in 24 hours).
Asterisk Fly can be used at any time of day. If symptom relief is not observed within 3 days after starting the drug, you should consult your doctor.
SIDE EFFECT
Allergic reactions (skin rash, itching, hives, angioedema), nausea, epigastric pain; anemia, thrombocytopenia, agranulocytosis. Increased excitability, dizziness, increased blood pressure, violation of falling asleep. Mydriasis, paresis of accommodation, increased intraocular pressure, dry mouth; retention of urine.
With prolonged use in large doses - hepatotoxic effect, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia; nephrotoxicity (renal colic, glucosuria, interstitial nephritis, papillary necrosis).
CONTRAINDICATIONS
hypersensitivity;
- children's age till 12 years;
- phenylketonuria;
- diabetes;
- portal hypertension;
- Alcoholism;
- kidney failure;
- Pregnancy;
- lactation period;
- deficiency of glucose-6-phosphate dehydrogenase;
- with the simultaneous administration of tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, beta-blockers.
Carefully
Congenital hyperbilirubinemia (Gilbert syndrome, Dubin-Johnson and Rotor syndrome), children under 15 years, angle-closure glaucoma, prostatic hyperplasia, severe coronary artery atherosclerosis, arterial hypertension, hepatic and / or renal insufficiency, pheochromocytoma.
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in renal failure.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in liver failure.
APPLICATION FOR CHILDREN
Contraindicated for children under 12 years.
SPECIAL INSTRUCTIONS
During the treatment it is necessary to refrain from using ethanol (it is possible to develop a hepatotoxic effect).
Impact on the ability to drive vehicles and manage mechanisms
It is necessary to refrain from driving motor vehicles and practicing other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
OVERDOSE
Symptoms (due to paracetamol): pallor of the skin, decreased appetite, nausea, vomiting; hepatonecrosis (the severity of necrosis due to intoxication directly depends on the degree of overdose). Toxic effect in adults is possible after taking more than 10-15 g of paracetamol: increased activity of "liver" transaminases,
increased prothrombin time (12-48 hours after administration); a detailed clinical picture of liver damage manifests itself after 1-6 days. Rarely, liver failure develops at a lightning speed and can be complicated by renal insufficiency (tubular necrosis).
Treatment: introduction of donors of SH-groups and precursors of glutathione-methionine synthesis 8-9 hours after an overdose and N-acetylcysteine ​​after 12 hours.
The need for additional therapeutic measures (further introduction of methionine, intravenous injection of N-acetylcysteine) is determined depending on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration.
DRUG INTERACTION
Strengthens the effects of MAO inhibitors, sedatives, ethanol.
Ethanol enhances the sedative effect of the phenyramine, which is part of the drug.
Phenyramin simultaneously with MAO inhibitors, furazolidone can lead to hypertensive crisis, agitation, hyperpyrexia.
Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of urinary retention, dry mouth, constipation.
Glucocorticosteroids (GCS) increase the risk of increased intraocular pressure.
Paracetamol reduces the effectiveness of uricosuric medicines and improves the effectiveness of indirect anticoagulants.
Tricyclic antidepressants enhance the sympathomimetic effect, the simultaneous administration of halothane increases the risk of ventricular arrhythmia.
Reduces the hypotensive effect of guanethidine, which in turn increases the alpha-adrenostimulating activity of phenylephrine.
TERMS OF RELEASE FROM PHARMACY
Without recipe.
TERMS AND CONDITIONS OF STORAGE
In a dry, dark place at a temperature of 15 to 25 В° C. Keep out of the reach of children. Shelf life - 3 years.
